🔴 United Therapeutics is trading 4.65% down today; cause remains unclear

United Therapeutics is trading at $488.88, down -4.65%, with the immediate cause unclear.

• No clear negative company-specific catalyst was identified for September 2, 2026.
• United Therapeutics announced FDA acceptance of nebulized Tyvaso for idiopathic pulmonary fibrosis; review is expected by late April 2027, and the indication remains investigational.
• The decline is occurring despite broader equities and biotechnology trading higher.